Mereo BioPharma Group PLC ADR is a biotechnology business based in the US. Mereo BioPharma Group PLC ADR shares (MREO) are listed on the NASDAQ and all prices are listed in US Dollars. Mereo BioPharma Group PLC ADR employs 33 staff and has a trailing 12-month revenue of around $1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.43 |
|---|---|
| 52-week range | $1.07 - $5.02 |
| 50-day moving average | $4.02 |
| 200-day moving average | $3.29 |
| Wall St. target price | $7.17 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.25 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.43 from 2024-09-03
| 1 week (2024-08-29) | -3.28% |
|---|---|
| 1 month (2024-08-05) | 13.59% |
| 3 months (2024-06-05) | 26.57% |
| 6 months (2024-03-05) | 18.45% |
| 1 year (2023-09-05) | 207.64% |
|---|---|
| 2 years (2022-09-02) | 314.02% |
| 3 years (2021-09-03) | 61.09% |
| 5 years (2019-09-05) | 23.40% |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $936,000 |
| Return on assets TTM | -23.86% |
| Return on equity TTM | -48.47% |
| Profit margin | 0% |
| Book value | $0.51 |
| Market Capitalization | $721.6 million |
TTM: trailing 12 months
We're not expecting Mereo BioPharma Group PLC ADR to pay a dividend over the next 12 months.
Over the last 12 months, Mereo BioPharma Group PLC ADR's shares have ranged in value from as little as $1.07 up to $5.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mereo BioPharma Group PLC ADR's is 0.975. This would suggest that Mereo BioPharma Group PLC ADR's shares are less volatile than average (for this exchange).
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.